ReviewJournal of clinical and experimental dentistry2017
Sjogren's syndrome: Review of the aetiology, Pathophysiology & Potential therapeutic interventions.
Review in Journal of clinical and experimental dentistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- The Effectiveness and Safety of Total Glucosides of Paeony in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- Comparative Utility of Tear Film and Ocular Surface Parameters in Differentiating Sjögren's Disease Dry Eye From Non-Sjögren's Dry Eye.Translational vision science & technology · 2026Article
- Deciphering the molecular landscape of Sjögren's disease, mucosa-associated lymphoid tissue lymphoma, and thyroid cancer: unraveling the complexities of disease mechanisms and diagnostic biomarkers.Clinical rheumatology · 2026Article
- Assessing the Independent and Combined Effects of Hyperosmolarity and Inflammatory Stress on Human Corneal Epithelial Cells.Investigative ophthalmology & visual science · 2025Article
- Ophthalmologic and serologic predictors of positive minor salivary gland biopsy in suspected Sjögren's disease.Scientific reports · 2025Article
- Predicting autoimmune thyroiditis in primary Sjogren's syndrome patients using a random forest classifier: a retrospective study.Arthritis research & therapy · 2025Article
- Exosomes in Systemic Autoimmune Diseases: Recent Advances in Diagnostic Biomarkers and Therapeutic Applications.International journal of nanomedicine · 2025Review
- Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sjögren's syndrome in mice by promoting TEC kinase degradation.Acta pharmacologica Sinica · 2024Article
- Advances in Sjögren's Syndrome Dry Eye Diagnostics: Biomarkers and Biomolecules beyond Clinical Symptoms.Biomolecules · 2024Review
- Emerging treatment for Sjögren's disease: a review of recent phase II and III trials.Expert opinion on emerging drugs · 2023Review
- Root Canal Infection and Its Impact on the Oral Cavity Microenvironment in the Context of Immune System Disorders in Selected Diseases: A Narrative Review.Journal of clinical medicine · 2023Review
- An Overview of the Dry Eye Disease in Sjögren's Syndrome Using Our Current Molecular Understanding.International journal of molecular sciences · 2023Review
- Extracellular vesicles as a new horizon in the diagnosis and treatment of inflammatory eye diseases: A narrative review of the literature.Frontiers in immunology · 2023Review
- Identification of Sjögren's syndrome patient subgroups by clustering of labial salivary gland DNA methylation profiles.PloS one · 2023Article
- Salivary and Lacrimal Gland Alterations of the Epidermal Fatty Acid-Binding Protein (E-FABP) in Non-Obese Diabetic Mice.International journal of molecular sciences · 2022Article
- PI3K/AKT/mTOR Signaling Pathway Is Downregulated by Runzaoling (RZL) in Sjögren's Syndrome.Mediators of inflammation · 2022Article
- Blocking IAgLife sciences · 2022Article
- Using hierarchical similarity to examine the genetics of Behçet's disease.BMC research notes · 2021Article
- SPM Receptor Expression and Localization in Irradiated Salivary Glands.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2021Article
- CP-25 alleviates antigen-induced experimental Sjögren's syndrome in mice by inhibiting JAK1-STAT1/2-CXCL13 signaling and interfering with B-cell migration.Laboratory investigation; a journal of technical methods and pathology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSjogren's syndrome (SS) is an autoimmune disorder characterised by lymphocytic infiltration of exocrine glands, resulting in glandular dysfunction. Objectives: This study aims to review the aetiology of Sjogren's syndrome, highlight aspects that contribute to the pathophysiology of the disease and explore treatment options that target different mediators of pathogenesis. MATERIAL AND
methodsThe MEDLINE/PubMed and Google Scholar databases were searched systematically with the terms "Sjogren's syndrome"; "clinical"; "treatment"; "management". Eligible studies had to meet a predefined inclusion criteria.
results912 identified studies were evaluated against the inclusion criteria. 25 eligible studies were included for review. Sjogren's syndrome is a multifactorial condition with genetic, environmental and hormonal factors playing a role in establishing the condition. B-cell activating factor (BAFF) is an important mediator in the induction and perpetuation of this condition. Elevated BAFF levels, found in patients with SS, promote growth of B-cells and subsequent production of autoantibody; anti-SSA/Ro. BAFF inhibitors are important potential therapeutic drugs that may be effective in patients with Sjogren's syndrome. Other potential targets include CD20 and CD22 that cause B-cell depletion.
conclusionsThe pathophysiology of this exocrinopathy has not fully been elucidated. Potential therapeutic interventions include BAFF inhibitors and anti-CD20 and anti-CD22 therapy. However, no clinical trials have been conducted on subjects with Sjogren's syndrome to support existing research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.